摘要
目的探讨CT导向下125I粒子植入治疗肺癌患者的疗效及预后生存分析。方法回顾性分析103例肺癌患者的临床资料,通过观察患者治疗后的临床疗效以评估其应用价值,并采用Kaplan-Meier法对患者的临床资料进行单因素分析,Cox回归模型进行多因素分析。结果 103例肺癌患者1年、2年、3年的生存率分别为55.3%、16.5%、2.9%,中位生存期17.6个月;单因素分析结果显示:吸烟史、病理类型、TNM分期、脑转移、胸腔积液及治疗方法与患者的预后相关;Cox回归多元分析显示:脑转移、治疗方式及TNM分期与其预后有关,而吸烟史、病理类型、胸腔积液与其预后无关。结论125I粒子植入治疗肺癌患者临床疗效明显且安全可靠;脑转移、治疗方式及TNM分期可作为肺癌患者的独立预后因素。
Objective To observe the clinical efficacy and prognosis of CT-guided125 I seed implantation for lung cancer.Methods Clinical data of 103 lung cancer patients were retrospectively analyzed.To assess the clinical value of CT-guided125 I seed implantation for lung cancer.Univariate and multivariate analysis were performed by Kaplan-Meier methods and Cox regression model respectively.Results The 1-,2-,3-year overall survival rates were 55.3%,16.5%,2.9%,and median survive duration was 17.6months; The univariate analysis showed that survival was correlated with smoking history,pathological classification,TNM-staging,brain metastasis,pleural effusion,and therapy modality.Multivariate analysis showed that TNM-staging,brain metastasis and therapy modality were not related with prognosis.Conclusion The clinical therapeutic effect of125 I radioactive seed implantation for lung cancer patients is definite,and adverse reactions are endurable,the TNM staging,brain metastasis and therapy modality may be considered as important index for predicting prognosis of lung cancer patients.
出处
《实用癌症杂志》
2015年第11期1639-1642,共4页
The Practical Journal of Cancer
